“Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 2, no. S1 (February 23, 2018): S22. Accessed May 22, 2026. https://skin.dermsquared.com/skin/article/view/305.